International Assets Investment Management LLC Invests $950,000 in Hologic, Inc. (NASDAQ:HOLX)

International Assets Investment Management LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,290 shares of the medical equipment provider's stock, valued at approximately $950,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Hologic in the fourth quarter worth $27,000. Venturi Wealth Management LLC acquired a new stake in shares of Hologic in the third quarter worth $29,000. NBC Securities Inc. acquired a new stake in shares of Hologic in the third quarter worth $33,000. Deseret Mutual Benefit Administrators increased its stake in shares of Hologic by 42.2% in the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 155 shares during the period. Finally, Massmutual Trust Co. FSB ADV increased its stake in shares of Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 227 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

HOLX traded up $0.97 during midday trading on Tuesday, hitting $77.19. 1,603,272 shares of the company traded hands, compared to its average volume of 1,797,643. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $18.12 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 2.55 and a beta of 1.00. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The business has a 50 day simple moving average of $75.87 and a two-hundred day simple moving average of $72.69.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company's revenue was down 5.7% compared to the same quarter last year. During the same period last year, the firm posted $1.07 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of the firm's stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company's stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company's stock, valued at $3,670,130.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,846 shares of company stock valued at $2,473,443. Corporate insiders own 1.75% of the company's stock.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of research reports. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Evercore ISI raised their price target on shares of Hologic from $76.00 to $78.00 and gave the company an "in-line" rating in a research report on Thursday, April 4th. Raymond James raised their price target on shares of Hologic from $85.00 to $88.00 and gave the company an "outperform" rating in a research report on Friday, February 2nd. William Blair restated an "outperform" rating on shares of Hologic in a research report on Friday, February 2nd. Finally, StockNews.com lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Friday, March 8th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.